Over 7,000 Volunteers Recruited in Q1 This Year!

Posted:
7
June 2004

Richmond Pharmacology is delighted to announce we recruited over 7,000 new volunteers between January and March of 2004. This takes the total number of volunteers registered to over 25,000 in just 2 years.Quarter two looks set to yield similar recruitment figures, with over 2,300 new volunteers registering every month. The result is a testimony to Richmond Pharmacology’s dedicated volunteer recruitment team:Wendy Galloway, Head of Volunteer Recruitment, commented: “Obviously the whole team is delighted with the results of our recruitment programme. Our wide ranging advertising campaigns are drawing in thousands of enquiries to our recruitment website www.trials4us.co.uk and our telerecruitment team. Richmond Pharmacology is conducting an ever growing number of studies, which puts the onus on successful, targeted volunteer recruitment. It means we are able to guarantee delivery of whatever type of volunteer panel our clients require. I look forward to continuing to grow our volunteer database at such a fast rate.”

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more